Samsung Electronics has released a fascinating update to the Samsung Health Monitor app. The U.S. Food and Drug Administration (FDA) has approved the app’s Irregular Heart Rhythm Notification (IHRN) function. Samsung customers can actively monitor atrial fibrillation (AFib) rhythms from their wrist with the help of the Galaxy Watch.
The FDA has approved the Irregular Heart Rhythm Notification, created to assist millions worldwide who might not be aware of potential heart risks. Hon Pak, Vice President and Head of the Digital Health Team, MX Business at Samsung Electronics, expressed his excitement about the FDA clearance. Samsung’s proactive safety solutions provide a comprehensive view of cardiovascular and general health for consumers.
Technology-Assisted Management of Cardiovascular Risks
AFib, a kind of arrhythmia, is a warning sign for severe cardiovascular problems that can increase the risk of stroke, heart failure, and other consequences. Cardiovascular disease is still the leading cause of death worldwide. Unbelievably, some AFib patients are asymptomatic or have no outward symptoms, making people ignorant of their potential hazards.
To address this issue, Samsung’s Galaxy Watch provides functions that help consumers understand their heart health. Among these devices is the Samsung BioActive Sensor, which permits on-demand Electrocardiogram (ECG) recording and has an HR Alert feature to identify irregular heart rhythms. Galaxy Watch users can monitor critical health aspects with the newly added IHRN capability.
How the IHRN Feature Operates
IHRN function silently operates in the background after activation on Samsung Health Monitor app using BioActive Sensor. It continually monitors for abnormal cardiac rhythms, and if a certain number of measures in a row reveal an abnormality, the watch alerts the wearer of possible AFib activity. Then, the instruction guides the user to perform an ECG on their watch for a more precise reading.
Limitations and Availability
One UI 5 Watch will have Irregular Heart Rhythm Notification, while following Galaxy Watch devices to receive later this year. After that, earlier models in the Galaxy Watch line will receive an extension. Remember that the IHRN function is not intended for users with other known arrhythmias or users younger than 22. For clinical interpretation and counseling, users should consult a licensed healthcare practitioner since it doesn’t aim to notify every AFib episode.
Additionally, the Samsung Health Monitor app is only usable on watches and smartphones bought in regions where the service is now offered due to market constraints in acquiring approval/registration as a Software as a Medical Device (SaMD). When visiting nations without assistance, users could encounter service limitations.
Giving Users the Power to Improve Their Heart Health
FDA approval of Samsung’s IHRN function shows dedication to proactive safety and providing consumers comprehensive cardiovascular health information. Samsung aims to aid millions globally with practical heart health monitoring solutions, raising awareness of potential cardiac risks. With the development of the Samsung Health Monitor app, users can expect improved health management and informed well-being decisions.